Advertisement
UK markets closed

  • FTSE 100

    8,139.83
    +60.97 (+0.75%)
     

  • FTSE 250

    19,824.16
    +222.18 (+1.13%)
     

  • AIM

    755.28
    +2.16 (+0.29%)
     

  • GBP/EUR

    1.1675
    +0.0019 (+0.16%)
     

  • GBP/USD

    1.2491
    -0.0020 (-0.16%)
     

  • Bitcoin GBP

    50,923.66
    -778.07 (-1.50%)
     

  • CMC Crypto 200

    1,324.00
    -72.53 (-5.19%)
     

  • S&P 500

    5,111.18
    +62.76 (+1.24%)
     

  • DOW

    38,305.04
    +219.24 (+0.58%)
     

  • CRUDE OIL

    83.95
    +0.38 (+0.45%)
     

  • GOLD FUTURES

    2,346.50
    +4.00 (+0.17%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     

  • DAX

    18,161.01
    +243.73 (+1.36%)
     

  • CAC 40

    8,088.24
    +71.59 (+0.89%)
     
PROPERTY:

9 luxury homes to consider if money is no object

Ever thought about what a multimillion pound budget would buy you?

Lonza concludes peptides business sale, books charges

Reuters - UK Focus

ZURICH, Jan 4 (Reuters) - Lonza has concluded the divestment of its peptides business in Belgium to PolyPeptide Laboratories Holding, the Swiss group said on Wednesday. It gave no financial terms.

"As announced (in) early December, Lonza has booked a non-cash related write-off of 44 million Swiss francs ($42.8 million). Furthermore, Lonza will also book a 29 million franc non-cash currency translation impact in the first half of 2017," it said.

($1 = 1.0279 Swiss francs) (Reporting by Michael Shields, editing by John Revill)